ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Bunter62
|
86 |
15K |
12 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
86
|
15K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
Bunter62
|
29 |
4.8K |
6 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
29
|
4.8K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Bunter62
|
86 |
15K |
33 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
86
|
15K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Bunter62
|
86 |
15K |
28 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
86
|
15K
|
28
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
9 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
476
|
108K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Bunter62
|
10K |
4.7M |
4 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
10K
|
4.7M
|
4
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
Bunter62
|
15 |
4.5K |
5 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
15
|
4.5K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Bunter62
|
85 |
20K |
8 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Bunter62
|
85 |
20K |
28 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
28
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
6 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
476
|
108K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Bunter62
|
85 |
20K |
24 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Bunter62
|
85 |
20K |
24 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
24
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
11 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
476
|
108K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Pharmaust Investor Update
|
|
Bunter62
|
20 |
5.5K |
10 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
20
|
5.5K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
12 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
476
|
108K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
16 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
476
|
108K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Bunter62
|
58 |
15K |
23 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
58
|
15K
|
23
|
|
ASX - By Stock
|
BRN |
Re:
Ann: Annual General Meeting Results
|
|
Bunter62
|
144 |
47K |
5 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
144
|
47K
|
5
|
|
ASX - By Stock
|
BRN |
Re:
2024 BrainChip Discussion
|
|
Bunter62
|
5.7K |
2.2M |
1 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
5.7K
|
2.2M
|
1
|
|
ASX - By Stock
|
BRN |
Re:
2024 BrainChip Discussion
|
|
Bunter62
|
5.7K |
2.2M |
21 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
5.7K
|
2.2M
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
7 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
476
|
108K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
5 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
476
|
108K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
6 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
476
|
108K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
3 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
476
|
108K
|
3
|
|
ASX - By Stock
|
BRN |
Re:
Ann: Annual General Meeting Addresses and Presentation
|
|
Bunter62
|
72 |
28K |
30 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
72
|
28K
|
30
|
|
Charts
|
HZR |
Re:
HZR Chart
|
|
Bunter62
|
2.2K |
699K |
2 |
21/05/24 |
21/05/24 |
Charts
|
2.2K
|
699K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Charlie and the once in a lifetime post!
|
|
Bunter62
|
52 |
17K |
3 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
52
|
17K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
12 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
476
|
108K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Charlie and the once in a lifetime post!
|
|
Bunter62
|
52 |
17K |
0 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
52
|
17K
|
0
|
|
ASX - By Stock
|
MNB |
Re:
Ann: Phosphate Fertilizer Project Update
|
|
Bunter62
|
319 |
57K |
13 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
319
|
57K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
20 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
476
|
108K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Bunter62
|
476 |
108K |
17 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
476
|
108K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Bunter62
|
58 |
15K |
16 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
58
|
15K
|
16
|
|
ASX - By Stock
|
BGL |
Re:
Ann: Commercial production declared & expansion studies commence
|
|
Bunter62
|
109 |
42K |
0 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
109
|
42K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
8 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
8 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
9 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Bunter62
|
86 |
20K |
1 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
Bunter62
|
43 |
11K |
14 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
43
|
11K
|
14
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Bunter62
|
1.7K |
889K |
4 |
16/05/24 |
16/05/24 |
Charts
|
1.7K
|
889K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Bunter62
|
42 |
9.4K |
10 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
42
|
9.4K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Bunter62
|
10K |
4.7M |
20 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
10K
|
4.7M
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Bunter62
|
42 |
9.4K |
20 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
42
|
9.4K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Bunter62
|
42 |
9.4K |
13 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
42
|
9.4K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Bunter62
|
42 |
9.4K |
10 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
42
|
9.4K
|
10
|
|
ASX - By Stock
|
BGL |
Re:
Ann: Commercial production declared & expansion studies commence
|
|
Bunter62
|
109 |
42K |
3 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
109
|
42K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Bunter62
|
42 |
9.4K |
12 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
42
|
9.4K
|
12
|
|